HOOKIPA Pharma
HOOK
HOOK was delisted on the 7th of August, 2025.
49 hedge funds and large institutions have $69M invested in HOOKIPA Pharma in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 18 reducing their positions, and 5 closing their positions.
40% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 5
4% more funds holding
Funds holding: 47 → 49 (+2)
0.1% less ownership
Funds ownership: 3.44% → 3.34% (-0.1%)
21% less capital invested
Capital invested by funds: $87.2M → $69M (-$18.2M)
28% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 18
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $209K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.81M |
| 2 |
BlackRock
New York
|
+$360K |
| 3 |
Russell Investments Group
London,
United Kingdom
|
+$198K |
| 4 |
MAM
Martingale Asset Management
Boston,
Massachusetts
|
+$153K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$105K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SB
Samsara BioCapital
Palo Alto,
California
|
-$2.89M |
| 2 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$592K |
| 3 |
Renaissance Technologies
New York
|
-$290K |
| 4 |
Millennium Management
New York
|
-$234K |
| 5 |
RG
Redmile Group
San Francisco,
California
|
-$181K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Jane Street
New York
| – | -$137K | -1,176 | Closed |
|
52
Two Sigma Investments
New York
| – | -$133K | -1,146 | Closed |
|
53
RhumbLine Advisers
Boston,
Massachusetts
| – | -$127K | -1,093 | Closed |
|
|
PFWA
54
Paces Ferry Wealth Advisors
Atlanta,
Georgia
| – | +$306 | +3 | New |
|
HOOK Hedge Fund Activity: Q3 2020 in Review
49 of the 4,956 institutional investors tracked by Wall St. Rank reported a position in HOOKIPA Pharma (HOOK) for Q3 2020, worth a combined $69M — down 21% from $87.2M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new HOOK positions and 5 closed out — a net gain of 2 holders — while 13 added to existing stakes and 18 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.81M. The largest seller was Samsara BioCapital, cutting an estimated $2.89M.
- 49 institutional investors held HOOKIPA Pharma (HOOK) as of Q3 2020, up from 47 in Q2 2020.
- Funds reported $69M of HOOKIPA Pharma stock for Q3 2020, down 21% quarter-over-quarter.
- 7 funds opened new HOOKIPA Pharma positions in Q3 2020 and 5 closed out, a net change of +2 holders.
- The largest HOOKIPA Pharma buyer in Q3 2020 was Vanguard Group, an estimated $1.81M added.
- The largest HOOKIPA Pharma seller in Q3 2020 was Samsara BioCapital, an estimated $2.89M sold.
Based on aggregated 13F filings for Q3 2020.